TY - JOUR
T1 - A National Seroepidemiologic Survey of Pertussis among School Children in Taiwan
AU - on behalf of the TPIDA
AU - Lu, Chun Yi
AU - Tsai, Hsing Chen
AU - Huang, Yhu Chering
AU - Huang, Daniel Tsung Ning
AU - Liu, Ching Chuan
AU - Huang, Li Min
N1 - Publisher Copyright:
Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.
PY - 2017/7/20
Y1 - 2017/7/20
N2 - BACKGROUND:: In 2009, a booster dose of acellular pertussis vaccine for children at or before entry to elementary school was added to the national immunization program in Taiwan, which includes pertussis vaccination at 2, 4, 6, and 18 months of age. In 2013, a study to assess the level of humoral immunity against pertussis in elementary and junior high school children and adolescents was conducted. METHODS:: A multistage stratified systematic sampling method was applied to randomly selected grade 1 to 9 school children for testing. Serum samples were tested for IgG antibodies to Bordetella pertussis using commercial ELISA kits. The study collected information on socio-demographic characteristics, vaccination history, sibling number, and disease history of pertussis. RESULTS:: The study recruited 2,782 school children from 58 schools around the country. By questionnaire, only 1% (28/2,782) students had history of pertussis. The overall positivity rate of anti-B. pertussis IgG was 42.5%, and the rates were not different between the 5 geographical areas (range from 39.6% to 44.6%. P=0.375). Age-stratified data showed that the positivity rates were 43.6-48.8% among Grade 1-3 students, 26.6-28.7% in Grade 4-5 students, and increased progressively from 39.4% to 51.3% in Grade 6-9 students. The overall positivity rate was significantly higher in the non-booster group (46.4% vs. 38.6%, P<0.01). CONCLUSION:: The prevalence of anti-B. pertussis antibody was 42.5% in Grade 1-9 students under the current vaccination program in Taiwan. Antibody induced by the booster vaccination before entry of primary school waned rapidly in 3-4 years. Rapid waning of anti-B. pertussis antibody may explain the resurgence of whooping cough in recent decades. Additional booster doses should be considered in adolescents and adults.
AB - BACKGROUND:: In 2009, a booster dose of acellular pertussis vaccine for children at or before entry to elementary school was added to the national immunization program in Taiwan, which includes pertussis vaccination at 2, 4, 6, and 18 months of age. In 2013, a study to assess the level of humoral immunity against pertussis in elementary and junior high school children and adolescents was conducted. METHODS:: A multistage stratified systematic sampling method was applied to randomly selected grade 1 to 9 school children for testing. Serum samples were tested for IgG antibodies to Bordetella pertussis using commercial ELISA kits. The study collected information on socio-demographic characteristics, vaccination history, sibling number, and disease history of pertussis. RESULTS:: The study recruited 2,782 school children from 58 schools around the country. By questionnaire, only 1% (28/2,782) students had history of pertussis. The overall positivity rate of anti-B. pertussis IgG was 42.5%, and the rates were not different between the 5 geographical areas (range from 39.6% to 44.6%. P=0.375). Age-stratified data showed that the positivity rates were 43.6-48.8% among Grade 1-3 students, 26.6-28.7% in Grade 4-5 students, and increased progressively from 39.4% to 51.3% in Grade 6-9 students. The overall positivity rate was significantly higher in the non-booster group (46.4% vs. 38.6%, P<0.01). CONCLUSION:: The prevalence of anti-B. pertussis antibody was 42.5% in Grade 1-9 students under the current vaccination program in Taiwan. Antibody induced by the booster vaccination before entry of primary school waned rapidly in 3-4 years. Rapid waning of anti-B. pertussis antibody may explain the resurgence of whooping cough in recent decades. Additional booster doses should be considered in adolescents and adults.
UR - http://www.scopus.com/inward/record.url?scp=85025630874&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85025630874&partnerID=8YFLogxK
U2 - 10.1097/INF.0000000000001711
DO - 10.1097/INF.0000000000001711
M3 - Article
C2 - 28737625
AN - SCOPUS:85025630874
JO - Pediatric Infectious Disease Journal
JF - Pediatric Infectious Disease Journal
SN - 0891-3668
ER -